We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Radioactive Gold Nanoparticles Shrink Prostate Tumors in Mouse Model

By LabMedica International staff writers
Posted on 02 Aug 2012
Radioactive gold nanoparticles conjugated to a compound that specifically binds to a receptor present on prostate cancer cells have been used to halt the growth of aggressive prostate tumors in a mouse xenograft model.

Investigators at the University of Missouri (Columbia, USA) created targeted radioactive nanoparticles by conjugating prostate tumor specific epigallocatechin-gallate (EGCg) to gold nanoparticles derived from the Au-198 isotope. More...
EGCg binds with excellent affinity to Laminin67R receptors, which are over expressed in prostate tumor cells while Au-198, which has a half-life of 2.7 days, emits a deadly beta particle that is able to penetrate approximately 11 mm in tissue (approximately 1100 cell diameters). This range is sufficiently long to deliver a lethal radiation dose to cells within the prostate gland and short enough to minimize the radiation dose to adjacent critical tissues.

Radioactive gold nanoparticles were administered to SCID mice carrying prostate cancer PC-3 xenografts. Results published in the July 16, 2012, online edition of the journal Proceedings of the National Academy of Sciences of the USA (PNAS) revealed that approximately 72% of the 198AuNP-EGCg nanoparticles became sequestered in tumors 24 hours after intratumoral administration. Therapeutic studies showed 80% reduction of tumor volumes after 28 days, demonstrating significant inhibition of tumor growth compared to controls.

"In our study, we found that a special compound in tea was attracted to tumor cells in the prostate," said senior author Dr. Kattesh Katti, professor of radiology and at the University of Missouri. "When we combined the tea compound with radioactive gold nanoparticles, the tea compound helped "deliver" the nanoparticles to the site of the tumors and the nanoparticles destroyed the tumor cells very efficiently."

Related Links:

University of Missouri




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.